High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes.

Venous thromboembolism (VTE), a common condition associated with substantial morbidity and mortality, occurs in 1-3 per 1000 of the population (http://www.dh.gov.uk/ PolicyAndGuidance/HealthAndSocialCareTopics/BloodSafety/ VTE/DVT/DVTGeneralArticle/fs/en?CONTENT_ID¼4123480 c 339 women) VTE patients for survival and occurrence of malignancy. Patients were followed for a median of 23 months. 17AE2% patients had a d-dimer level >8000 ng FEU/mlat presentation, which was associated with decreased overall survival (OS) (P 8 mg/l when compared with 13AE4% of patients with VTE without malignancy (P 8000 ng FEU/mlas compared with 13AE3% of patients with VTE with out malignancy (P ¼ 0AE009). In conclusion, d-dimer >8000 ng FEU/ml at presentation in patients with VTE is a marker of poor OS, EFS and underlying malignancy. Consideration of screening for malignancy is recommended in patients with VTE with a presentation d-dimer >8000 ng FEU/ml and age >60 years.